Product Center
The first phase of the vaccine industrialization project was successfully completed
- Categories:Industry news
- Author:
- Origin:
- Time of issue:2017-08-30
- Views:
(Summary description)The human vaccine industrialization project of Ab&B Bio-Tech CO.,LTD.JS. covers an area of 70 mu, with a planned construction area of 50,000 square meters. The first-phase construction projects include: R&D complex building, production workshop 1, animal room, and central laboratory. The single building, with a total of 30,000 square meters, was successfully completed on August 30, 2017, and then entered the stage of decoration and process construction to prepare for clinical trials in 2018.
The first phase of the vaccine industrialization project was successfully completed
(Summary description)The human vaccine industrialization project of Ab&B Bio-Tech CO.,LTD.JS. covers an area of 70 mu, with a planned construction area of 50,000 square meters. The first-phase construction projects include: R&D complex building, production workshop 1, animal room, and central laboratory. The single building, with a total of 30,000 square meters, was successfully completed on August 30, 2017, and then entered the stage of decoration and process construction to prepare for clinical trials in 2018.
- Categories:Industry news
- Author:
- Origin:
- Time of issue:2017-08-30 10:57
- Views:
The human vaccine industrialization project of Ab&B Bio-Tech CO.,LTD.JS. covers an area of 70 mu, with a planned construction area of 50,000 square meters. The first-phase construction projects include: R&D complex building, production workshop 1, animal room, and central laboratory. The single building, with a total of 30,000 square meters, was successfully completed on August 30, 2017, and then entered the stage of decoration and process construction to prepare for clinical trials in 2018.
Relevant information
-
Breaking through bottleneck technology, significant progress has been made in the research and development of new adjuvantsOn August 25th, the R&D team of Yither Biotech (Shanghai) Co., Ltd, a wholly-owned subsidiary of Ab&B Bio Tech Co., Ltd (locally referred to as "Zhonghui Bio"), made a breakthrough in the field of innovative adjuvant research and development. The research results were published online in the internationally renowned journal "Journal of Drug Delivery Science and Technology" under the title "Dual functional Emulsifier Based Nano Emulsification Adjuvant Effectively Enhanced Immunogenicity of Recombinant Respiratory Syncytial Virus Vaccine in Mice". - Obtained recognition as one of the first offshore innovation centers for enterprises in Taizhou 08-14
- Recombinant herpes zoster vaccine (CHO cells) IND application approved 08-13
- IND application for quadrivalent influenza virus subunit vaccine (adjuvant) approved 07-30
- World Influenza Conference 2024 | Decoding new possibilities for the future of influenza vaccines 07-09
Have a project？Get a touch!
Caring for life, protecting health, and making global technological innovation vaccines are the mission of Ab&B Bio
Contact
E-mail:info@abbbio.com.cn
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
